Quantcast

Latest Glycoproteins Stories

2014-02-07 12:39:53

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections. If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of new antibacterial therapies. The protein's unique ability to...

2014-02-06 16:26:57

LA JOLLA, Calif., Feb. 6, 2014 /PRNewswire-USNewswire/ -- A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections. If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of...

2014-01-31 23:24:23

OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays. Rockville, MD (PRWEB) January 31, 2014 Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), an approach developed by Dr. Leigh Anderson, is a novel technology that can achieve high...

2014-01-31 08:24:48

ALBANY, New York, January 31, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Endocrine Testing Market (E2, FSH, hCG, LH, DHEAS, Progesterone, Testosterone, TSH, Prolactin, Cortisol, Insulin Tests and Others)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global endocrine testing market was valued at USD1.53billion in 2012 and is estimated to reach a market worth USD2.03 billion in 2019...

2014-01-30 11:07:19

University of British Columbia researchers have discovered a potential new treatment for a rare blood cancer that may also point the way to treating other more common diseases. Paroxysmal nocturnal hemoglobinemia (PNH) is a rare form of cancer characterized by episodic rupture of red blood cells and the danger of blood clots forming in the vascular system. The condition results in red blood cells becoming vulnerable to attacks by the body's own complement immune system and can lead to...

2014-01-23 04:21:26

LONDON and BOSTON, January 23, 2014 /PRNewswire/ -- Stabilised GPCR (StaR(R)) Proteins Delivered For All Nominated Targets Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, has successfully completed the research phase of its antibody drug discovery collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. In achieving this milestone, Heptares has delivered StaR(R) proteins...

2014-01-16 23:27:40

Study indicates potential for TauC3 to be disease-modifying. Englewood Cliffs, New Jersey (PRWEB) January 16, 2014 Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its...

2014-01-13 12:28:06

LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg. Debiopharm is investigating the efficacy and safety of...

2014-01-13 08:27:35

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome(TM) nanocage technology originally developed by Chimeros, Inc. The foundation of Chimerasome technology is a single protein that can be manipulated to form a spherical protein shell, which can encapsulate drugs and be coupled to antibodies externally, allowing very specific cellular targeting of the...

2014-01-10 08:23:51

First-in-class program for the treatment of atopic dermatitis and allergic diseases SAN DIEGO, Jan. 10, 2014 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the development of a first-in-class therapeutic antibody to interleukin-33 (IL-33). Discovered using the Company's proprietary SHM-XEL platform, AnaptysBio's anti-IL-33 lead candidate antibody (ANB020) inhibits IL-33 cytokine function by blocking interaction with its receptor at...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related